Abstract
Background: Although several therapeutic agents have been evaluated for the treatment of COVID-19, none has yet been shown to be effective. Large Randomized Control trials are required to see the efficacy of current medical treatment.Objective: Evaluating the role of N2N parallel therapy for adult COVID-19 patients with lower respiratory tract infection for early discharge from hospital or keeping in hospital for infection control only.Holistic Med provides a Complementary and Alternative medical platform together with an Integrative approach incorporating timely prescribed Conventional Medicine to achieve complete cure.Case History: A 57-years old emergency physician developed symptoms of high grade fever, cough, loss of appetite, body aches & fatigue. He tested positive for Covid-19 and was started on antiretroviral and antimalarial therapy as per the Dubai Health Authority (DHA) Protocol. He received the current medical treatment for four days without any improvement in his condition. His treatment was tailored by adding N2N Parallel Therapy for 72 hours followed by continuity of care.Results: Tailored treatment through the use of acute detox, ingestion of anti-oxidants, Intermittent Fasting, using micronutrients, oxygen supplement and intake of steroid during the 2nd phase of treatment. The results were promising which helped avert an ICU admission. Improvement in health was also seen in the form of better lab results and exercise tolerance while hospitalization. This therapy if applied will reduce ICU admissions, duration of hospital-stay and mortality rate.Conclusion: N2N Parallel Therapy is superior to the current medical treatment in terms of early discharge of adult hospitalized COVID-19 patients with evidence of lower respiratory tract infection. Overall, to reduce morbidity & mortality.
Highlights
1.1 Overview Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus that was first recognized in Wuhan, China, in December 2019
As of November 17, 2020, there have been more than 50 million reported cases and 1.3 million deaths worldwide. This novel Beta-coronavirus is similar to severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East Respiratory Syndrome coronavirus (MERS-CoV) (2,4). 1.2 Objective The purpose of this case study is to evaluate the role of N2N parallel treatment of Nature Therapy in COVID-19 and determine the effective outcome of the treatment
Inclusion criteria consisted of full text articles, studies conducted on COVID-19 treatment and pandemic relation, articles published in English language from the time period of 2019-2020
Summary
1.1 Overview Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus that was first recognized in Wuhan, China, in December 2019. Case History: A 57-years old emergency physician developed symptoms of high grade fever, cough, loss of appetite, body aches & fatigue He tested positive for Covid-19 and was started on antiretroviral and antimalarial therapy as per the Dubai Health Authority (DHA) Protocol. He received the current medical treatment for four days without any improvement in his condition. His treatment was tailored by adding N2N Parallel Therapy for 72 hours followed by continuity of care. Improvement in health was seen in the form of better lab results and exercise tolerance while hospitalization This therapy if applied will reduce ICU admissions, duration of hospital-stay and mortality rate. Conclusion: N2N Parallel Therapy is superior to the current medical treatment in terms of early www.scholink.org/ojs/index.php/csm
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
